Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

Sarepta Therapeutics' Elevidys gene therapy is under FDA investigation following two reported fatal cases of acute liver failure in non-ambulatory pediatric Duchenne Muscular Dystrophy patients, causing SRPT stock to fall 9.96%. This prompted HC Wainwright to reiterate a Sell rating with a $10 price target, as analysts anticipate the FDA will at minimum mandate updated labeling or, in a worst-case scenario, withdraw Elevidys, which they believe would significantly diminish Sarepta's intrinsic value, a risk compounded by prior skepticism from CBER head Vinay Prasad regarding the therapy's initial approval.

Analysis

Sarepta Therapeutics is facing a significant regulatory and commercial threat following the FDA's investigation into two fatal cases of acute liver failure linked to its Duchenne Muscular Dystrophy (DMD) gene therapy, Elevidys. The investigation, prompted by reports from clinical trials and postmarketing data involving non-ambulatory pediatric patients, has triggered a sharp market reaction, with SRPT stock declining 9.96% to $17.09. Reinforcing this negative sentiment, HC Wainwright reiterated its Sell rating with a $10 price target. The core of the risk lies in the potential for severe FDA action, which analyst Mitchell Kapoor suggests could range from a mandatory label update detailing the risk of death to a worst-case scenario of a complete market withdrawal. This latter outcome is presented as an existential risk, with the analyst stating that if Elevidys were withdrawn, there would be "little intrinsic value remaining in the company." This risk is further amplified by the reported pre-existing skepticism from CBER head Vinay Prasad regarding the drug's initial approval, suggesting a potentially unfavorable regulatory disposition towards Sarepta.

Key Decisions for Investors

• Investors should recognize the heightened idiosyncratic risk, as the potential withdrawal of Elevidys could, according to analyst commentary, eliminate the majority of the company's intrinsic value.
• Closely monitor all forthcoming FDA communications and regulatory panel discussions, as these will be the primary catalysts determining the future of Elevidys and SRPT's stock performance.
• Consider the severe downside scenario presented by HC Wainwright's $10 price target, which implies a near-total loss of value from the company's flagship therapy and suggests a re-evaluation of long positions is warranted given the binary nature of the outcome.